URGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Urogen Pharma Ltd (URGN) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available for investment. The company's strong Phase 3 data for Zusduri, bullish technical indicators, hedge fund buying activity, and favorable analyst rating with a $40 price target make it an attractive opportunity. Despite short-term financial losses, the significant revenue growth and gross margin improvement signal long-term potential.
The technical indicators are bullish. The MACD histogram is positive at 0.63, showing upward momentum. The RSI is neutral at 63.481, and moving averages are bullish with SMA_5 > SMA_20 > SMA_200. Key resistance levels are R1: 26.512 and R2: 28.341, while support levels are S1: 20.591 and S2: 18.762.
Hedge funds are significantly increasing their positions, with a 194.83% increase in buying over the last quarter.
Analyst Amin Makarem from Jefferies initiated coverage with a Buy rating and a $40 price target, citing strong Phase 3 data for Zusduri.
Revenue growth of 54.03% YoY in Q4 2025 and gross margin improvement to 91.31%.
Net income dropped by 29.72% YoY in Q4 2025, and EPS declined by 16.92%.
No recent news or congress trading data to provide additional sentiment or validation.
Options data shows a higher put volume relative to calls, with a Put-Call Volume Ratio of 1.63, indicating some bearish sentiment.
In Q4 2025, revenue increased by 54.03% YoY to $37.84 million, and gross margin improved to 91.31%. However, net income dropped by 29.72% YoY to -$26.36 million, and EPS fell by 16.92% to -0.54.
Jefferies analyst Amin Makarem initiated coverage with a Buy rating and a $40 price target, highlighting strong Phase 3 data for Zusduri and favorable risk/reward potential.
